Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of QX027N in inadequately controlled moderate-to-severe asthma
ChiCTR2600136027Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of QX027N in asthma (4 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Change from baseline in pre-bronchodilator FEV1 at Week 12. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
QX027N
03
Conditions
asthma
Beyond the preview
Go deeper on ChiCTR2600136027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600136027.